StockNews.AI
ENSC
StockNews.AI
209 days

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

1. Positive Phase 1b data shows overdose protection for PF614-MPAR. 2. Clinical study evaluates PF614-MPAR's safety in severe pain relief.

2m saved
Insight
Article

FAQ

Why Bullish?

Successful trial outcomes often lead to increased investor confidence, boosting stock price.

How important is it?

Clinical trial results are crucial in the pharmaceutical sector, especially for pipeline products.

Why Short Term?

Positive trial results can quickly influence stock performance but depend on further developments.

Related Companies

ENSC
~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced interim data from its second clinical trial to evaluate PF614-MPAR for overdose protection. Clinical study PF614-MPAR-102, ‘A Single and Multiple Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 when PF614 Capsule is Co‑Administered with Nafamostat as a Combination of Immediate Release Solution and Extended Release Capsule Formulations (PF614-MPAR) in Healthy Subjects,' was designed to evaluate the full dosage range of PF614-MPAR, study potential food effects, and to conduct a multiple ascending dose study with the final PF614-MPAR combination.

Related News